Will the Private Medical Cannabis Market Shrink if NHS Access Opens Up?

As medical cannabis becomes an increasingly discussed therapeutic option in the UK, many wonder how NHS prescribing might impact the existing private market. The debate often centres on whether NHS availability will reduce the need for private medical cannabis providers or if private clinics will continue to play a vital role. Understanding the nuances here requires separating legality from practical access, recognising current regulatory frameworks—especially in England—and examining how speed, choice, and funding gaps shape patient experiences.

Legality vs Real-World Access: The Foundation of the Debate

In November 2018, the UK government legalised medical cannabis by rescheduling https://todaynews.co.uk/2026/08/10/inside-the-uks-private-medical-cannabis-clinics-how-the-sector-actually-works/ certain cannabis-based products for medicinal use. This made it legal for healthcare professionals on the General Medical Council (GMC) Specialist Register to prescribe these products. However, legalisation did not automatically mean widespread availability or NHS funding.

Despite the legality, NHS prescriptions have remained extremely limited, chiefly restricted to a small number of specialist consultants treating a narrow range of conditions (for example, some cases of epilepsy and multiple sclerosis). Consequently, many patients whose clinicians lack specialist status or experience must turn to private providers to obtain cannabis medicines—a situation often termed a two-tier access system.

The Private Market's Role in the Current Healthcare Landscape

The private market fills a significant access gap left by the NHS's cautious approach. Private clinics, typically staffed by specialists registered with the GMC, offer consultations—often by video—and remote prescribing services. This means patients can initiate or continue treatment more rapidly and with greater choice than the NHS currently offers.

It’s important to note that in England, private clinics conducting video consultations and offering remote prescribing must register with the Care Quality Commission (CQC), which regulates healthcare providers to safeguard patient safety. This regulatory oversight is vital, distinguishing legitimate providers from less scrupulous operators that blur medical prescribing with wellness marketing.

The NHS Funding Gap and Private Market Reality

Though medical cannabis products are legal and prescribable, the NHS rarely funds them. The ongoing funding gap arises from:

• Lack of robust, large-scale clinical trial data convincing NHS decision-makers.
• Cost concerns: Medical cannabis tends to be expensive, especially relative to conventional alternatives.
• Complex commissioning pathways and conservative prescribing culture.

As a result, patients face a choice: either wait on the NHS’s slow-changing access or pay privately for prescriptions and consultations. This dynamic maintains substantial demand for private clinics, where patients have quicker access and a broader range of products. Studies and anecdotal evidence confirm that private providers meet demand unmet by the NHS.

Common Mistake: Omission of Pricing Transparency

A frequent issue in private medical cannabis advertising is the lack of clarity on consultation and prescription costs. Patients must understand the entire financial commitment upfront. For example:

• Consultation fees: Video or in-person medical assessments can range substantially (£150 to £300 or more).
• Prescription costs: Medical cannabis medicines themselves are typically not subsidised and can cost several hundred pounds monthly.
• Follow-up appointments: These are often necessary, adding ongoing costs.

Without transparent pricing, potential patients risk unexpected expenses or discontinuity of care. Responsible providers clearly state these fees and any obligations tied to prescriptions.

Who Can Prescribe Medical Cannabis and Why It Matters

Not every doctor can prescribe medical cannabis. By law, only doctors listed on the GMC Specialist Register are eligible. This typically includes consultants specialising in fields like neurology, pain medicine, or oncology who have relevant experience.

General practitioners (GPs) and other healthcare professionals—even if medically qualified and registered—cannot initiate medical cannabis prescriptions outside specialist status. This ensures clinical prudence but also restricts volume prescribing, affecting NHS-wide availability.

Video Consultations and Remote Prescribing

Innovations like video consultations and remote prescribing have become widespread due to patient convenience and the COVID-19 pandemic. Private providers in England offering these services must notify or register with the CQC to comply with regulatory standards.

This framework ensures that remote clinical assessments meet quality and safety criteria. It also governs record-keeping, safeguarding against improper prescribing. NHS-funded clinics, possessing inpatient or outpatient infrastructure, may have more comprehensive governance but often lack the agility of private setups.

The Regulatory Landscape and CQC Oversight in England

The Care Quality Commission plays a critical role in regulating private providers offering remote consultations and prescriptions. Their responsibilities include:

• Ensuring clinical standards are met
• Inspecting facilities and processes, even remotely delivered services
• Handling complaints or safety concerns
• Verifying that providers declare remote prescribing activities

This oversight contrasts with many wellness or supplement providers who often operate outside these controls, blurring healthcare boundaries.

Will NHS Access Shrink the Private Medical Cannabis Market?

While improving NHS access sounds promising, several factors suggest the private market will persist for the foreseeable future:

1. The NHS is not planning widespread prescribing yet. Current NHS access remains limited to tightly defined indications and specialist clinics.
2. Speed and choice remain private market strengths. Patients seeking rapid initiation or specific formulations unlikely on the NHS will continue to turn to private clinics.
3. The funding gap will not close overnight. NHS decisions on coverage involve lengthy reviews, budget negotiations, and policy shifts.
4. Two-tier situations persist. Those who can afford private clinics gain earlier and easier access, while others wait on NHS routes.

Summary Checklist: Key Differences Between NHS and Private Medical Cannabis Access

Aspect NHS Access Private Market Legality Legal but restricted prescribing Legal prescribing by GMC specialists Prescribers qualified Specialist consultants on GMC Specialist Register Same criteria, often consultant-level doctors Funding Usually NHS-funded if prescribed Self-funded by patient Speed of Access Often slow, due to limited clinics and cautious approach Generally faster, with video consultations and remote prescriptions Choice of product Limited formulary Broader range of cannabis-based products Regulation and Oversight (England) NHS governance structures CQC regulated for remote prescribing activities Price Transparency Free at point of care Varies; must include consultation, prescription and follow-up costs

Conclusion

The opening of NHS access to medical cannabis, while desirable, is unlikely to render the private market obsolete. Instead, it will create a complex, two-tiered landscape where private providers offer valuable speed and choice for patients needing timely therapeutic options. Crucially, the legal ability to prescribe medical cannabis is tightly linked to specialists on the GMC register, and regulatory oversight, such as the CQC in England, ensures private providers maintain clinical standards—especially when offering video consultations and remote prescribing.

For patients, the key is clear, upfront information—particularly around consultation fees and prescription costs—to make informed choices in this evolving treatment area.